These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 10198732)
1. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis. Oriana S; Coradini D; Sasso GM; Di Fronzo G Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861 [TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF. Campora E; Pronzato P; Amoroso D; Bertelli GF; Venturini M; Baldini E; Brunetti I; Sertoli MR; Conte P; Rosso R Anticancer Res; 1992; 12(5):1555-8. PubMed ID: 1444221 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Søreide JA; Lea OA; Varhaug JE; Skarstein A; Kvinnsland S Eur J Surg Oncol; 1992 Apr; 18(2):112-8. PubMed ID: 1582503 [TBL] [Abstract][Full Text] [Related]
6. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group. Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant cytostatic therapy of breast cancer as an important factor in the postponing of a relapse and longer survival period. Stula N Acta Med Croatica; 1992; 46(2):101-11. PubMed ID: 1384832 [TBL] [Abstract][Full Text] [Related]
8. West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. Morrison JM; Kelly KA; Howell A; Grieve RJ; Monypenny IJ; Walker RA; Waterhouse JA J Natl Cancer Inst Monogr; 1992; (11):85-8. PubMed ID: 1627435 [TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemotherapy therapy of breast cancer]. Koyama H; Noguchi S; Inaji H; Motomura K; Imaoka S; Iwanaga T Gan To Kagaku Ryoho; 1992 Jun; 19(6):775-82. PubMed ID: 1605653 [TBL] [Abstract][Full Text] [Related]
10. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen. Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310 [TBL] [Abstract][Full Text] [Related]
11. Progesterone-binding cyst protein (PBCP) in operable breast cancer: correlations with prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Søreide JA; Lea OA; Anda O; Skarstein A; Varhaug JE; Kvinnsland S Anticancer Res; 1991; 11(2):601-5. PubMed ID: 2064314 [TBL] [Abstract][Full Text] [Related]
12. A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group). Goldhirsch A; Castiglione M; Gelber RD J Natl Cancer Inst Monogr; 1992; (11):89-96. PubMed ID: 1627436 [TBL] [Abstract][Full Text] [Related]
13. [The adjuvant chemotherapy of breast cancer]. Semiglazov VF; Golubeva OM; Bavli IaL; Ivanova OA; Topuzov EE Vopr Onkol; 1992; 38(10):1187-94. PubMed ID: 1343144 [TBL] [Abstract][Full Text] [Related]
14. Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases. Salvadori B; Rovini D; Squicciarini P; Conti R; Cusumano F; Grassi M Eur J Surg Oncol; 1992 Oct; 18(5):438-41. PubMed ID: 1426293 [TBL] [Abstract][Full Text] [Related]
15. The role of chemotherapy for node-negative breast cancer. Cooper MR Cancer; 1991 Mar; 67(6 Suppl):1744-7. PubMed ID: 2001570 [TBL] [Abstract][Full Text] [Related]
16. [Value of thymidine kinase in the prediction of response to treatment by chemotherapy or hormone therapy in breast cancer]. Bennini N; Mauriac L; Wafflart J; Bonichon F; Durand M Bull Cancer; 1992; 79(8):773-9. PubMed ID: 1467600 [TBL] [Abstract][Full Text] [Related]
17. Classical prognostic factors in node-negative breast cancer: the DBCG experience. Mouridsen HT; Andersen J; Andersen KW; Axelsson C; Blichert-Toft M; Dombernowsky P; Hansen M; Krag C; Overgård M; Rasmussen BB J Natl Cancer Inst Monogr; 1992; (11):163-6. PubMed ID: 1627423 [TBL] [Abstract][Full Text] [Related]
18. [The role of tumor receptor status in choosing adjuvant therapy for breast cancer patients of reproductive age]. Samgina AA; Letiagin VP; Kuz'mina ZV Vopr Onkol; 1992; 38(7):780-7. PubMed ID: 1300782 [TBL] [Abstract][Full Text] [Related]
19. Swiss adjuvant trials in women with node-negative breast cancer. OSAKO. Jungi WF; Senn HJ J Natl Cancer Inst Monogr; 1992; (11):71-6. PubMed ID: 1627433 [TBL] [Abstract][Full Text] [Related]
20. Evolving concepts in the systemic adjuvant treatment of breast cancer. Bonadonna G Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216 [No Abstract] [Full Text] [Related] [Next] [New Search]